Literature DB >> 25288423

The 340B drug discount program: hospitals generate profits by expanding to reach more affluent communities.

Rena M Conti1, Peter B Bach2.   

Abstract

The federal 340B program gives participating hospitals and other medical providers deep discounts on outpatient drugs. Named for a section of the Veterans Health Care Act of 1992, the program's original intent was to help low-income and uninsured patients. But the program has come under scrutiny by critics who contend that some hospitals exploit the drug discounts to generate profits instead of either investing in programs for the poor or passing the discounts along to patients and insurers. We examined whether the program is expanding in ways that could maximize hospitals' ability to generate profits from the 340B drug discounts. We matched data for 960 hospitals and 3,964 affiliated clinics registered with the 340B program in 2012 with the socioeconomic characteristics of their communities from the US Census Bureau's American Community Survey. We found that hospital-affiliated clinics that registered for the 340B program in 2004 or later served communities that were wealthier and had higher rates of health insurance compared to communities served by hospitals and clinics that registered for the program before 2004. Our findings support the criticism that the 340B program is being converted from one that serves vulnerable patient populations to one that enriches hospitals and their affiliated clinics. Project HOPE—The People-to-People Health Foundation, Inc.

Entities:  

Keywords:  Hospitals; Medicare; Pharmaceuticals

Mesh:

Substances:

Year:  2014        PMID: 25288423      PMCID: PMC4591849          DOI: 10.1377/hlthaff.2014.0540

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  13 in total

1.  Oncology Practice Trends From the National Practice Benchmark, 2005 through 2010.

Authors:  Thomas R Barr; Elaine L Towle
Journal:  J Oncol Pract       Date:  2011-09       Impact factor: 3.840

2.  Hospitals' geographic expansion in quest of well-insured patients: will the outcome be better care, more cost, or both?

Authors:  Emily R Carrier; Marisa Dowling; Robert A Berenson
Journal:  Health Aff (Millwood)       Date:  2012-04       Impact factor: 6.301

3.  Hospital-physicians relations: cooperation, competition, or separation?

Authors:  Robert A Berenson; Paul B Ginsburg; Jessica H May
Journal:  Health Aff (Millwood)       Date:  2006-12-05       Impact factor: 6.301

4.  Proportion of physicians in large group practices continued to grow in 2009-11.

Authors:  W Pete Welch; Alison Evans Cuellar; Sally C Stearns; Andrew B Bindman
Journal:  Health Aff (Millwood)       Date:  2013-09       Impact factor: 6.301

5.  Hospitals, market share, and consolidation.

Authors:  David M Cutler; Fiona Scott Morton
Journal:  JAMA       Date:  2013-11-13       Impact factor: 56.272

6.  Hospitals' race to employ physicians--the logic behind a money-losing proposition.

Authors:  Robert Kocher; Nikhil R Sahni
Journal:  N Engl J Med       Date:  2011-03-30       Impact factor: 91.245

7.  Oncology practice trends from the national practice benchmark.

Authors:  Thomas R Barr; Elaine L Towle
Journal:  J Oncol Pract       Date:  2012-09       Impact factor: 3.840

8.  National Oncology Practice Benchmark, 2012 report on 2011 data.

Authors:  Elaine L Towle; Thomas R Barr; James L Senese
Journal:  J Oncol Pract       Date:  2012-10-02       Impact factor: 3.840

9.  Cost consequences of the 340B drug discount program.

Authors:  Rena M Conti; Peter B Bach
Journal:  JAMA       Date:  2013-05-15       Impact factor: 56.272

10.  The impact of patient assistance programs and the 340B Drug Pricing Program on medication cost.

Authors:  Yelba M Castellon; Shahrzad Bazargan-Hejazi; Miles Masatsugu; Roberto Contreras
Journal:  Am J Manag Care       Date:  2014-02       Impact factor: 2.229

View more
  17 in total

1.  Pharmacy accessibility and cost-related underuse of prescription medications in low-income Black and Hispanic urban communities.

Authors:  Dima Mazen Qato; Jocelyn Wilder; Shannon Zenk; Andrew Davis; Jennifer Makelarski; Stacy Tessler Lindau
Journal:  J Am Pharm Assoc (2003)       Date:  2017-01-30

2.  Consequences of the 340B Drug Pricing Program.

Authors:  Sunita Desai; J Michael McWilliams
Journal:  N Engl J Med       Date:  2018-05-24       Impact factor: 91.245

3.  Developing and Validating a Measure to Estimate Poverty in Medicare Administrative Data.

Authors:  Valerie A Lewis; Karen Joynt Maddox; Andrea M Austin; Daniel J Gottlieb; Julie P W Bynum
Journal:  Med Care       Date:  2019-08       Impact factor: 2.983

4.  Exploring the Healthcare Environment and Associations with Clinical Outcomes of People Living with HIV/AIDS.

Authors:  Mary Hawk; Robert W S Coulter; James E Egan; Mackey Reuel Friedman; Steven Meanley; Stuart Fisk; Courtney Watson; Suzanne Kinsky
Journal:  AIDS Patient Care STDS       Date:  2017-11-17       Impact factor: 5.078

5.  Consequences of the 340B Drug Pricing Program.

Authors:  Sunita Desai; J Michael McWilliams
Journal:  N Engl J Med       Date:  2018-01-24       Impact factor: 91.245

6.  Has The Era Of Slow Growth For Prescription Drug Spending Ended?

Authors:  Murray Aitken; Ernst R Berndt; David Cutler; Michael Kleinrock; Luca Maini
Journal:  Health Aff (Millwood)       Date:  2016-09-01       Impact factor: 6.301

7.  The 340B benefit program: Why we should care about both its intentions and outcomes.

Authors:  Saty Satya-Murti
Journal:  Neurol Clin Pract       Date:  2018-04

8.  Preserving Independent Urology: LUGPA's First Decade.

Authors:  Neal D Shore; Deepak A Kapoor; Evan R Goldfischer; David C Chaikin; Earl L Walz; R Jonathan Henderson; Richard G Harris; Robert D Asinof; Gary M Kirsh
Journal:  Rev Urol       Date:  2019

Review 9.  Review of Current Policy Strategies to Reduce US Cancer Drug Costs.

Authors:  Angela K Green; Jennifer A Ohn; Peter B Bach
Journal:  J Clin Oncol       Date:  2019-12-05       Impact factor: 44.544

10.  The unintended consequences of the 340B safety-net drug discount program.

Authors:  Samuel Thomas; Kevin Schulman
Journal:  Health Serv Res       Date:  2020-03-01       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.